Compare Natera Inc. Common Stock (NTRA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Upwork Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Upwork Inc trades at $8.58 (market cap $1.08B). The key difference: Natera Inc. Common Stock is far larger — about 52.8× Upwork Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Upwork Inc for 38 Days on average.
| NTRA | UPWK | |
|---|---|---|
Market Cap | $57.03B | $1.08B |
Volume | 1,131,157 | 2,181,968 |
Sector | Health | Industrials |
52-Week High | $425.64 | $22.11 |
52-Week Low | $179.42 | $7.84 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $56.18B | $842.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
UPWK trades at $8.43, down 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though recent earnings showed two misses out of three quarters. Revenue growth has slowed from 28.02% in 2024 to 14.65% in 2025, with Q3 2026 earnings pending. Institutional buying interest exists with Bank of America acquiring 704,083 shares in September 2026.
UPWK presents a compelling value case with low P/E of 11.08 and P/S of 1.49, trading below the $9.64 consensus target. However, AI disruption to freelance markets and declining active client counts pose significant risks. The stock offers 14% upside to analyst targets but faces execution challenges amid industry transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
